The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Enhancing myelofibrosis prognostication with machine learning
In this video, Adrian Mosquera Orgueira, MD, PhD, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain, discusses a study undertaken by the Spanish Registry of Myelofibrosis to improve prognostication for patients with myelofibrosis (MF). The team attempted to use machine learning (ML) to improve prognostication using clinical data for a large cohort of patients. The resulting tool provided an improved prognostication to standard algorithms, including the MIPSS70 in primary MF and the MYSEC-PM in secondary MF. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche, Amgen, AstraZeneca, Janssen, Abbvie, Takeda, Brystol, GSK, Pfizer,: Consultancy, Honoraria, Research Funding.
